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Abnormal plasma DNA profiles in early
ovarian cancer using a non-invasive
prenatal testing platform: implications
for cancer screening
Paul A. Cohen1,7,9*, Nicola Flowers3, Stephen Tong4,5, Natalie Hannan4,5, Mark D. Pertile3,8 and Lisa Hui2,4,5,6
Abstract
Background: Non-invasive prenatal testing (NIPT) identifies fetal aneuploidy by sequencing cell-free DNA in
the maternal plasma. Pre-symptomatic maternal malignancies have been incidentally detected during NIPT
based on abnormal genomic profiles. This low coverage sequencing approach could have potential for
ovarian cancer screening in the non-pregnant population. Our objective was to investigate whether plasma
DNA sequencing with a clinical whole genome NIPT platform can detect early- and late-stage high-grade
serous ovarian carcinomas (HGSOC).
Methods: This is a case control study of prospectively-collected biobank samples comprising preoperative
plasma from 32 women with HGSOC (16 ‘early cancer’ (FIGO I–II) and 16 ‘advanced cancer’ (FIGO III–IV)) and
32 benign controls. Plasma DNA from cases and controls were sequenced using a commercial NIPT platform
and chromosome dosage measured.
Sequencing data were blindly analyzed with two methods: (1) Subchromosomal changes were called using an
open source algorithm WISECONDOR (WIthin-SamplE COpy Number aberration DetectOR). Genomic gains or
losses ≥ 15 Mb were prespecified as “screen positive” calls, and mapped to recurrent copy number variations
reported in an ovarian cancer genome atlas. (2) Selected whole chromosome gains or losses were reported
using the routine NIPT pipeline for fetal aneuploidy.
Results: We detected 13/32 cancer cases using the subchromosomal analysis (sensitivity 40.6 %, 95 % CI,
23.7–59.4 %), including 6/16 early and 7/16 advanced HGSOC cases. Two of 32 benign controls had
subchromosomal gains ≥ 15 Mb (specificity 93.8 %, 95 % CI, 79.2–99.2 %). Twelve of the 13 true positive
cancer cases exhibited specific recurrent changes reported in HGSOC tumors. The NIPT pipeline resulted in
one “monosomy 18” call from the cancer group, and two “monosomy X” calls in the controls.
Conclusions: Low coverage plasma DNA sequencing used for prenatal testing detected 40.6 % of all HGSOC,
including 38 % of early stage cases. Our findings demonstrate the potential of a high throughput sequencing
platform to screen for early HGSOC in plasma based on characteristic multiple segmental chromosome gains
and losses. The performance of this approach may be further improved by refining bioinformatics algorithms
and targeting selected cancer copy number variations.
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Background
The detection and monitoring of specific cancer mutations
by sequencing circulating DNA holds much promise, but
has yet to be widely translated into clinical care. In con-
trast, sequencing plasma DNA during pregnancy to detect
fetal chromosomal abnormalities (non-invasive prenatal
testing, NIPT) has been rapidly implemented globally due
to its high accuracy and proven clinical validity [1].
Circulating DNA of tumor origin can interfere with
NIPT performance and produce abnormal genomic pro-
files that suggest occult malignancy in pregnant women
[2]. Amant et al. [3] recently reported the pre-symptomatic
identification of cancer in three pregnant women undergo-
ing NIPT, suggesting that genomic profiling for copy
number variations (CNVs) may be a feasible approach for
cancer screening. However, the sensitivity and specificity of
clinical NIPT platforms for cancer remains unknown.
Ovarian cancer is the leading cause of gynecologic
cancer-related deaths in developed countries [4] and there
is a pressing need for an effective screening test [5, 6].
High-grade serous ovarian cancer (HGSOC) accounts for
most deaths from the disease [7] and demonstrates a
marked chromosomal instability [8]. We hypothesized
that these tumor-derived chromosome abnormalities
would be detectable in the plasma of HGSOC patients
collected prior to primary surgery. The aims of this study
were to investigate whether a clinical NIPT platform could
detect HGSOC in the non-pregnant population based on
an abnormal plasma DNA profile, and to compare the
detection rates for early and advanced stage HGSOC.
Methods
We performed a case control study of 64 plasma samples
obtained from the Western Australia Gynecologic Oncol-
ogy Biospecimen Bank. These were prospectively collected
between January 2013 and August 2015 with informed
consent from patients prior to undergoing surgery. Ethical
approval was granted for this study.
The 32 cancer cases comprised 16 women with Inter-
national Federation of Gynecology and Obstetrics (FIGO)
stage I and II HGSOC (‘early cancer’), and 16 women with
FIGO stages III and IV HGSOC (‘advanced cancer’). The
control group included women with benign gynecologic
disease undergoing surgery (n = 24), or germline BRCA1
and BRCA2 mutation carriers without evidence of malig-
nancy who were undergoing risk-reduction surgery (n = 8).
DNA libraries, prepared from cell-free DNA extracted
from plasma, were sequenced on a commercial whole
genome NIPT platform using the standard workflow
employed for aneuploidy screening (percept™ prenatal
test, Victorian Clinical Genetics Services, Parkville VIC
Australia, based on Illumina’s verifi™ NIPT methodology
[2]). Each research sample was sequenced alongside 14
clinical samples, with 36-cycle single-end sequencing on
an Illumina NextSeq500. The read depth was low cover-
age at 0.2× to 0.3× based on 18–28 M × 36 bp single end
reads. Laboratory and analysis staff were blinded to the
case/control allocation of samples. Two types of data
analyses were performed.
(1) We used the open source algorithm WISECONDOR
(WIthin-SamplE COpy Number aberration
DetectOR) to detect whole chromosome and
subchromosomal abnormalities not identifiable by
the standard NIPT pipeline [9]. Segmental changes >
15 Mb were prespecified as abnormal calls
(“positive cancer screen”).
(2) We also analyzed the sequence data using the
routine clinical percept™ pipeline, developed to
detect fetal aneuploidy for chromosomes 21,
18, 13, X, and Y.
Paired tumor DNA was unavailable to correlate with
plasma sequencing data. We therefore compared the re-
sults of the WISECONDOR analysis with somatic CNVs
reported in the Integrated Genomic Analyses of Ovarian
Carcinoma (IGAOC) derived from 489 HGSOC tumor
genomes by The Cancer Genome Atlas Research
Network [8]. Our data were examined for recurrent
regional aberrations affecting extended chromosome
regions that were reported as statistically significant by
the IGAOC (8 gains and 22 losses).
Results
We detected 6/16 early stage and 7/16 advanced stage
HGSOC cases using the WISECONDOR analysis, giving
an overall detection rate of 13/32 (sensitivity 40.6 %,
95 % CI, 23.7–59.4 %). There were two false positive
calls in the control group (specificity 93.8 %, 95 % CI,
79.2–99.2 %) (Table 1).
Table 2 presents the specific CNVs detected in the 13
true positive cancer cases and the two false positive
Cohen et al. BMC Medicine  (2016) 14:126 Page 2 of 6
controls. Twelve of the 13 true positive cancer calls had a
CNV that was reported in The Cancer Genome Atlas
Network as statistically significant (FDR q value < 0.25) at
high frequency (>50 % of tumors). The most common
DNA amplifications observed in the 13 true positive calls
affected chromosome arms 3q (n= 5), 8q (n = 7), 20q (n= 4),
and 12p (n = 3). The most common DNA losses were seen
on chromosome arms 5q (n = 3), 8p (n = 3), 13q (n = 4),
and 15q (n = 3). Figure 1 shows the WISECONDOR plots
of sequenced cfDNA showing copy number variations of
chromosome 3 in the plasma of five subjects with high-
grade serous ovarian carcinomas.
The percept™ pipeline resulted in one “monosomy 18”
call from the cancer group, and two “monosomy X” calls
in the controls (Table 2). In five cancer cases and one con-
trol case, the pipeline failed to produce a result because of
unexpected profiles on normalizing chromosomes.
A post hoc analysis of our results showed that many
smaller focal aberrations identified by the IGAOC were
also present in the “screen positive” cancer cases. Most
of the cancer cases had multiple focal changes, whereas
none of the benign controls, including the two false positive
calls, had more than one focal change (Additional file 1).
The two false positives in the control groups in the
WISECONDOR analysis had single segmental gains on
20q. The clinical history of these controls included a
benign fallopian tube cyst in a patient with endomet-
riosis and a hemorrhagic follicular cyst in a patient
with a prior history of breast ductal carcinoma in situ
which had been completely excised prior to plasma
collection. Both patients were alive with no clinical
evidence of malignant or systemic disease at the time
of writing.
Discussion
In this proof of concept study, low coverage plasma DNA
sequencing and analysis for chromosomal CNVs ≥ 15 Mb
detected 40 % of HGSOC. Surprisingly, we detected simi-
lar proportions of early and advanced stage HGSOC
cancers with this approach. This finding was unex-
pected because one would assume a higher detection
rate in the advanced stage cases, given the lower
tumor bulk of early disease. This suggests that the
detection of ovarian tumor CNVs in plasma is not
directly related to cancer stage; other biological fac-
tors such as fractional concentration of tumor DNA
in plasma, tumor genetic heterogeneity, vascularity,
and cell turnover may also be important influences
on detection rates.
A limitation of our study was the inability to correlate
the plasma sequencing data with paired tumor DNA due
to the absence of suitable archived specimens. However,
the principle that tumor DNA is detectable in plasma
using NIPT sequencing platforms has been previously
established [2, 3]. Furthermore, the majority of genomic
aberrations detected in our cases included common im-
balances previously reported in a cohort of 489 HGSOC
specimens [8], supporting our assumption that the DNA
aberrations detected in plasma originated from ovarian
tumors.
Prior “liquid biopsy” studies in ovarian cancer have
relied on the identification of tumor-specific muta-
tions in advanced disease and the postoperative moni-
toring of patient-specific mutations in plasma via
deep sequencing [10, 11]. Our results are notable for
demonstrating that it is possible to detect early stage
ovarian cancer in the absence of patient-specific
tumor DNA using an existing low coverage sequen-
cing platform. Thus, high throughput whole genome
plasma sequencing, with or without the addition of
other biomarkers, is an exciting avenue for future
studies of cancer screening. It may have utility as a
cost-effective method of monitoring high risk patients
for whom tumor tissue is unavailable, such as pre-
symptomatic BRCA1/2 mutation carriers, or to assess
the preoperative risk of malignancy in patients pre-
senting with ovarian masses.
Potential reasons for the false positive WISECON-
DOR results in the two controls include technical issues
with the archived plasma samples or reference chromo-
some set. The two “monosomy X” calls in the NIPT
pipeline in the controls (aged 43 and 54 years) might
be explained by normal age-related X chromosome loss
[12] or low grade mosaicism [13]. It is plausible that,
with larger cohorts, algorithms could be devised that in-
crease test specificity. Further work is also required to
Table 1 Sequencing copy number variation calls using percept™ pipeline and WISECONDOR algorithm
Group Stage WISECONDOR call Percept™ call Total
Abnormal Normal Low risk No call High risk
Early HGSOC FIGO I–II 6 10 14 2 0 16
Advanced HGSOC FIGO III–IV 7 9 12 3 1a 16
Benign N/A 2 30 29 1 2b 32
aMonosomy 18 call
bTwo monosomy X calls
HGSOC, high grade serous ovarian carcinoma; FIGO, International Federation of Gynecology and Obstetrics
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Table 2 “Screen positive” copy number variations (CNVs) in 13 cancer cases and two controls mapped to reported gains and losses
in the Integrated Genomic Analysis of Ovarian Cancer (IGAOC) study [11]
Subject
number
Age
(years)
Study group FIGO Stage Percept™ call
for aneuploidy
Detected CNVs≥ 15 Mb mapped according to IGAOCa
Highly specific Moderately specific Non-specific
1 76 Early stage cancer 2C No call Chr 3q gain
Chr 12p gain
Chr 20q terminal gain
Chr 5q segmental loss
Chr 8p loss
Chr 9p loss
Chr 5p gain
Chr 7q segmental loss
2 65 Early stage cancer 2C No call Chr 3q terminal gain
Chr 20 gain
Chr 4q loss
Chr 7p loss
Chr 13q segmental loss
Chr 15q segmental loss
Chr 6p gain Chr 2q interstitial gain
Chr 18q segmental gain
3 48 Early stage cancer 1C Low risk Chr 12p terminal gain
4 71 Early stage cancer 2C Low risk Chr 3q interstitial gain
Chr 8q gain
5 38 Early stage cancer 1C Low risk Chr 8q terminal gain Chr 3p terminal gain
6 47 Early stage cancer 2A Low risk Chr 8q terminal gain
7 54 Advanced stage cancer 4 No call Chr 3q terminal gain
Chr 8 gain
Chr 5q loss
Chr 13 loss
Chr 15 loss
Chr 17 loss
Chr 18 loss
Chr 22 loss
Chr 14 loss Chr 5p gain
Chr 9p gain
8 57 Advanced stage cancer 3B Low risk Chr 8q terminal gain
Chr 8p terminal loss
Chr 1q interstitial gain
Chr 6p gain
Chr 1p interstitial gain
Chr 11q segmental gain
9 60 Advanced stage cancer 3A1 Low risk Chr 20 gain
10 83 Advanced stage cancer 3A Low risk Chr 11q interstitial gain
11 33 Advanced stage cancer 3C No call Chr 8q terminal gain
Chr 12p terminal gain
Chr 4q segmental loss
Chr 5q interstitial loss
Chr 6q terminal loss
Chr 8p loss
Chr 9p terminal loss
Chr 13 segmental loss
Chr 15 segmental loss
Chr 17q segmental loss
Chr 22 loss
Chr 6p segmental gains
Chr 7q segmental gains
Chr 1p segmental gains
Chr 2 segmental gains
Chr 5p gain
Chr 11q interstitial gain
Chr 18q segmental gain
Chr 1p segmental loss
Chr 10p loss
Chr 11q terminal loss
Chr 21 loss
12 58 Advanced stage cancer 3C No call Chr 3q gain
Chr 4p loss
Chr 9q loss
Chr 13 loss
Chr 1q gain
Chr 6p gain
Chr 7q terminal gain
Chr 11p loss
Chr 5p loss
Chr 7p terminal loss
Chr 10p gain
Chr 18 gain
13 66 Advanced stage cancer 3C Monosomy 18 Chr 20q gain
Chr 8q terminal
segmental gain
14 44 Benign control NA Low risk Chr 20q segmental gain
15 53 Benign control NA Low risk Chr 20q gain
aCNVs are categorized according to IGAOC analysis [8]. The IGAOC found 8 significantly gained chromosome arms (5 present in > 50 % of tumor samples), and 22
significantly deleted chromosome arms (18 present in > 50 %). We used the following definitions: highly specific CNV, statistically significant gain or loss (q value
< 0.25) with frequency in > 50 %; Moderately specific CNV, statistically significant gain or loss (q value < 0.25) with frequency in < 50 %; non-specific CNV, gain or
loss with q value > 0.25
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assess the technical issues with archived plasma samples
and to develop the clinical potential of this approach.
Conclusions
A low coverage plasma DNA sequencing protocol used in
a high throughput prenatal screening platform detected
more than one in three women with early stage ovarian
cancer based on common segmental chromosome gains
and losses. Further refinement of this approach may have
utility for future studies of ovarian cancer screening.
Additional file
Additional file 1: CNVs >15 Mb in the Western Australia Biospecimen
Bank Dataset, CNVs reported in an ovarian cancer genome atlas, and
coordinates of overlapping regions. (XLS 52 kb)
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Fig. 1 WISECONDOR plots of sequenced cfDNA showing copy number variations of chromosome 3 in the plasma of five subjects with high-grade
serous ovarian carcinomas. From top, Subject 1 diagnosed with a stage 2C, Subject 2 stage 2C, Subject 3 stage 4, Subject 4 stage 3C, Subject 5 stage
3C, and an Ideogram of chromosome 3. Y axis of plots depicts Z-score; red and blue lines are Z-score plotted by windowed and individual bin methods,
respectively. Pink and purple bars indicate deviation detected by windowed method or called by windowed method, respectively [12]. Subjects 1, 2, 3, and
5 show whole arm and/or segmental gains of chromosome 3q. Subject 4 shows segmental copy number losses within chromosome 3p and 3q
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